Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT ID: NCT00666211
Last Updated: 2012-09-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
98 participants
INTERVENTIONAL
2005-05-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase III trial is studying an Opioid Titration Order Sheet to see how well it works compared with standard care in treating patients with cancer pain.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pain Control in Hospice Patients With Cancer-Related Pain
NCT00609297
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
NCT05265052
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
NCT03455023
Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol
NCT01230515
Individualized Pharmaceutical-care in Outpatients With Cancer Pain
NCT03439904
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To examine the effect of an opioid titration order sheet on pain outcomes.
* To examine the effect of an opioid titration order sheet on secondary outcomes of function, mood, and quality of life.
OUTLINE: This is a multicenter study. Participating centers are randomized to 1 of 2 treatment arms.
* Arm I (usual care): After completion of baseline assessments, patients undergo a standardized pain education program over approximately 15 minutes. The program consists of standard written materials about communicating pain to providers, opioids and side effect management, as well as a tailored discussion about patient concerns and specific information about prescribed opioid medications. Patients are also instructed in the use of the daily pain diary. Patients are then discharged from the clinic with instructions to contact the treating physician (through standard procedures) for problems with pain or side effects. The study staff conducts weekly telephone interviews to prevent changes in patient pain management practice. The treating physician continues to manage pain in their usual manner.
* Arm II (opioid titration order sheet): After completion of baseline assessments, patients undergo the standardized pain education program and are instructed in the use of the daily pain diary as described in arm I. The treating physician signs an Opioid Titration Order Sheet (OTOS) providing a baseline dose and schedule. The OTOS is faxed to study staff and verified. Patients are then discharged from the clinic with instructions to contact the research nurse for problems with pain or side effects. The treating physician also contacts the study staff if he/she is made aware of any problems pertaining to the patient's pain control. The research nurse, in consultation with study physician, manages pain according to the OTOS and manages opioid side effects using standing orders. Referral to the treating physician is made as needed.
Patients' pain is managed on study for 8 weeks in the absence of unacceptable toxicity, pain crisis, or new site of pain.
Patients complete a demographic questionnaire at baseline and other questionnaires at 2, 4, and 6 weeks (over the telephone) and at 8 weeks (at site or by telephone), including the Functional Assessment Screening Questionnaire (FASQ), the Brief Pain Inventory-Interference (PPI-I), The Profile of Mood States-Short Form (POMS-SF), and the Quality of life (FACT-G) questionnaire. Patients also complete a pain diary recording daily measures of pain dimensions, analgesic use (i.e., fixed dose opioids, rescue doses, and non-opioids), adjuvant medications, and side effects that prevented the patient from taking medications. Data in the pain diary is transcribed over the telephone on a weekly basis.
Clinical data, including the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription, as well as information regarding analgesics (opioid and non-opioid), adjuvant medications, and medications to manage side effects prescribed during the study is collected from patients' medical records. Anticancer and palliative treatment received during the study is monitored via treating physician records.
The physician charts are reviewed after study completion to determine whether pain, treatment, and response are adequately documented and treated. The documentation in the physician charts is compared to the documentation obtained by the study staff during the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
Standard pain control drugs.
educational intervention
Participants will be educated on pain management.
questionnaire administration
Participants will be given questionnaires to complete.
Opioid Titration
Pain will be Monitored and Medication Titrated
educational intervention
Participants will be educated on pain management.
Titrated pain management
Pain will be Monitored and Medication Titrated
questionnaire administration
Participants will be given questionnaires to complete.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
educational intervention
Participants will be educated on pain management.
Titrated pain management
Pain will be Monitored and Medication Titrated
questionnaire administration
Participants will be given questionnaires to complete.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed carcinoma
* Cancer-related pain requiring fixed-dose opioid therapy
* Has received ≥ 1 week of fixed-dose opioid therapy AND meets any of the following criteria:
* Inadequate pain control as defined by the patient
* Requires 2 or more rescue doses per day
* Requires adjustments in pain regimen (either fixed or breakthrough dosing)
* No pain crisis that requires hospitalization or immediate anesthetic or neurosurgical intervention
* No predominantly neuropathic pain (e.g., peripheral neuropathy) as assessed by the treating physician
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* ANC \> 1,500/mm³
* Platelet count \> 100,000/mm³
* Serum bilirubin \< 1.5 mg/dL
* Serum creatinine \< 2.5 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Nutritional, pulmonary, and cardiac status must be considered adequate to tolerate the proposed study therapy
* Must be available for active follow-up
* No documented active psychiatric disorder (i.e., psychosis or major depression) that would preclude informed consent or the patient's ability to comply with study procedures
* No significant infection
* No concerns about compliance with medication regimens or medical follow-up
* No excessive alcohol use
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* Concurrent chemotherapy or radiotherapy allowed
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nancy Wells
Research Professor of Nursing; Director, VUMC Nursing; Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy Wells, DNSc, RN
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jennie Stuart Medical Center
Hopkinsville, Kentucky, United States
Mitchell Memorial Cancer Center at Owensboro Medical Health System
Owensboro, Kentucky, United States
Erlanger Health System
Chattanooga, Tennessee, United States
Tennessee Plateau Oncology
Crossville, Tennessee, United States
Center for Biomedical Research
Knoxville, Tennessee, United States
The Jones Clinic
Memphis, Tennessee, United States
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
Meharry Medical College
Nashville, Tennessee, United States
Veterans Affairs Medical Center - Nashville
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VU-VICC-SUPP-0424
Identifier Type: -
Identifier Source: secondary_id
VU-VICC-040410
Identifier Type: -
Identifier Source: secondary_id
VICC SUPP 0424
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.